These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20545217)

  • 1. [Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study].
    Kuwayama Y; Komemushi S;
    Nippon Ganka Gakkai Zasshi; 2010 May; 114(5):436-43. PubMed ID: 20545217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma.
    Shin J; Lee JW; Choi BS; Yun EY; Jung JH; Kim EA; Caprioli J
    J Ocul Pharmacol Ther; 2014 Dec; 30(10):803-9. PubMed ID: 25285367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less.
    Nakano T; Yoshikawa K; Kimura T; Suzumura H; Nanno M; Noro T
    Jpn J Ophthalmol; 2011 Nov; 55(6):605-13. PubMed ID: 21874307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
    Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
    Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
    Uusitalo H; Pillunat LE; Ropo A;
    Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
    Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence.
    Kuwayama Y; Hashimoto M; Kakegawa R; Nomura A; Shimada F
    Adv Ther; 2017 Jun; 34(6):1411-1425. PubMed ID: 28502035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.
    Kuwayama Y; Nomura A
    Adv Ther; 2014 Apr; 31(4):461-71. PubMed ID: 24615289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
    Erb C; Lanzl I; Seidova SF; Kimmich F
    Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of topical tafluprost on optic nerve head blood flow in patients with myopic disc type.
    Tsuda S; Yokoyama Y; Chiba N; Aizawa N; Shiga Y; Yasuda M; Yokokura S; Otomo T; Fuse N; Nakazawa T
    J Glaucoma; 2013; 22(5):398-403. PubMed ID: 23552835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males.
    Sutton A; Gilvarry A; Ropo A
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):359-65. PubMed ID: 17803434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.
    Keating GM
    Clin Drug Investig; 2016 Jun; 36(6):499-508. PubMed ID: 27225879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
    Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A
    Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
    Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
    Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.
    Uusitalo H; Kaarniranta K; Ropo A
    Acta Ophthalmol Suppl (Oxf ); 2008; 242():7-13. PubMed ID: 18752509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular pressure reduction with topical medications and progression of normal-tension glaucoma: a 12-year mean follow-up study.
    Kim M; Kim DM; Park KH; Kim TW; Jeoung JW; Kim SH
    Acta Ophthalmol; 2013 Jun; 91(4):e270-5. PubMed ID: 23406253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study.
    Lee W; Lee S; Bae H; Kim CY; Seong GJ
    BMC Ophthalmol; 2017 Apr; 17(1):61. PubMed ID: 28454526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies.
    Kaarniranta K; Ikäheimo K; Mannermaa E; Ropo A
    Clin Pharmacokinet; 2016 Apr; 55(4):485-94. PubMed ID: 26391697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preperimetric normal tension glaucoma study: long-term clinical course and effect of therapeutic lowering of intraocular pressure.
    Jeong JH; Park KH; Jeoung JW; Kim DM
    Acta Ophthalmol; 2014 May; 92(3):e185-93. PubMed ID: 24456145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.